Danazol in the treatment of myelodysplastic syndromes.
20 patients with myelodysplastic syndromes (MDS) were treated with danazol, 800 mg daily in 4 divided doses. 18 patients were evaluable for response. 3 patients (17%), whose principal problem was anemia, responded to treatment, but only with an increase in platelet count. Responses were short-lived and lacked clinical significance. No patients with anemia or leukopenia responded to treatment and none of the 7 patients with a platelet count less than 30 x 10(9)/l responded. Danazol appears to have limited clinical utility in the treatment of MDS. However, occasional patients with thrombocytopenia may benefit.
Buzaid
A C
AC
Arizona Cancer Center, Tucson.
Garewal
H S
HS
Lippman
S M
SM
Durie
B G
BG
Katakkar
S B
SB
Greenberg
B R
BR
D002986:Clinical Trials as Topic; D003613:Danazol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D011245:Pregnadienes / Q000627:therapeutic use*
D011245:Pregnadienes; D003613:Danazol